EndoGastric Solutions said today it launched its EsophyX Z device designed for treating gastroesophageal reflux disease, and that the device was used in its 1st treatment procedure.
The 1st procedure was performed during a transoral incisionless fundoplication procedure at Cali.’s U.C. Irvine Health by Dr. Kenneth Chang, the Redmond, Wash.-based company said.
“There are certain GERD patients who don’t respond effectively to medical management with proton pump inhibitors. Long-term data continue to demonstrate the positive impact the TIF procedure for reflux has in controlling chronic, troublesome GERD symptoms,” Dr. Chang said in a prepared statement.
The EsophyX Z device is designed for the reconstruction of the gastroesophageal valve through a partial fundoplication procedure, performed transorally.
“We are excited and honored to have Dr. Chang perform the first TIF procedure using the new EsophyX Z device via the TIF 2.0 procedure to treat a chronic GERD patient. This marks another notable milestone for EGS as we continue to address the significant problem of GERD and focus on filling the treatment gap between medication and more invasive surgery,” CEO Skip Baldino said in a press release.
The company said it is entering a limited U.S. release with a full commercialization of the product planned this summer.
In December, EndoGastric Solutions said it raised $50 million in a new round of financing for its EsophyX acid reflux treatment device.
The round was led by CRG and joined by existing EGS investors Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, Foundation Medical Partners and Radius Ventures, the Redmond, Wash.-based company said
Funds from the round will be used to enhance commercialization and continue R&D of the company’s next generation products for use in its proprietary TIF procedure.